Fig. 6From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a studyDose–response curve for PQ912 with regard to target (QC enzyme) occupancy. bid twice daily, QC glutaminyl cyclaseBack to article page